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Abstract
Omega-3 and omega-6 fatty acids are biosynthetic precursors to endocannabinoids with 
antinociceptive, anxiolytic, and neurogenic properties. We recently reported that targeted dietary 
manipulation—increasing omega-3 fatty acids while reducing omega-6 linoleic acid (the H3-L6 
intervention)—reduced headache pain and psychological distress among chronic headache 
patients. It is not yet known whether these clinical improvements were due to changes in 
endocannabinoids and related mediators derived from omega-3 and omega-6 fatty acids. We 
therefore used data from this trial (n=55) to investigate (1) whether the H3-L6 intervention altered 
omega-3 and omega-6 derived endocannabinoids in plasma, and (2) whether diet-induced changes 
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in these bioactive lipids were associated with clinical improvements. The H3-L6 intervention 
significantly increased the omega-3 docosahexaenoic acid derivatives 2-docosahexaenoylglycerol 
(+65%, p<0.001) and docosahexaenoylethanolamine (+99%, p<0.001), and reduced the omega-6 
arachidonic acid derivative 2-arachidonoylglycerol (-25%, p=0.001). Diet-induced changes in 
these endocannabinoid derivatives of omega-3 docosahexaenoic acid, but not omega-6 arachidonic 
acid, correlated with reductions in physical pain and psychological distress. These findings 
demonstrate that targeted dietary manipulation can alter endocannabinoids derived from omega-3 
and omega-6 fatty acids in humans, and suggest that 2-docosahexaenoylglycerol and 
docosahexaenoylethanolamine could have physical and/or psychological pain modulating 
properties. Trial Registration: ClinicalTrials.gov (NCT01157208)
Perspective—This article demonstrates that targeted dietary manipulation can alter 
endocannabinoids derived from omega-3 and omega-6 fatty acids, and that these changes are 
related to reductions in headache pain and psychological distress. These findings suggest that 
dietary interventions could provide an effective, complementary approach for managing chronic 
pain and related conditions.
Keywords
endocannabinoids; psychological distress; headache; 2-docosahexaenoylglycerol; 
docosahexaenoylethanolamine; 2-arachidonoylglycerol
Introduction
Omega-3 (n-3) and omega-6 (n-6) fatty acids are major components of immune and 
neuronal cell membranes35 and the biosynthetic precursors to several families of lipid 
autacoids posited to modulate physical pain and psychological distress (e.g. eicosanoids, 
endovanilloids, endocannabinoids)8-10, 20, 32, 38, 42. Humans lack the enzymatic machinery 
needed for de novo biosynthesis of n-3 and n-6 fatty acids. Therefore, targeted dietary 
manipulation is a promising strategy for altering bioactive lipid autacoids in a manner that 
could reduce pain and comorbid conditions. We recently tested this hypothesis in a 
population with chronic headaches.
The Chronic Daily Headache (CDH) trial
The CDH trial was a randomized, 12-week trial designed to test the clinical and biochemical 
effects of a diet high in n-3 and low in n-6 fatty acids (the H3-L6 intervention) compared to 
a diet low in n-6 fatty acids (the L6 intervention) in a population with CDH. We previously 
reported that the H3-L6 intervention produced marked reductions in headache frequency and 
severity 30, reduced psychological distress 29, and enhanced quality of life and function 29 
compared to the L6 intervention, while reducing the use of acute pain medications 30 . Diet-
induced changes in one or more families of n-3 or n-6 derived lipid autacoids likely 
contributed to these clinical benefits; however the specific lipid autacoids responsible for 
these effects are unknown. In the present manuscript, we investigate whether changes in one 
such family of lipid autacoids—endocannabinoids and related mediators derived from n-6 
and n-3 fatty acids—could help explain the beneficial effects of the H3-L6 intervention.
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n-6 and n-3 fatty acids as precursors to endocannabinoids and related 
mediators
The n-6 arachidonic acid (n-6 AA) derivatives 2-arachidonoylglycerol (2-AG) and N-
arachidonoylethanolamine (AEA) (Figure 1) have complex relationships with chronic pain 
and psychological distress. 2-AG and AEA act as endogenous ligands for cannabinoid 
receptors (i.e., endocannabinoids) to produce analgesic and anxiolytic effects 1, 8, 12, 33. 
However, in addition to activating cannabinoid receptors, 2-AG also serves as a major 
source for production free AA and prostanoids 4, 28, which have been implicated in 
headache pathogenesis 3. AEA is also the best-characterized endogenous ligand for the 
TRPV1 receptor channel (i.e., endovanilloid), which is involved in pain signaling 10.
The n-3 DHA derivatives 2-docosahexaenoylglycerol (2-DHG) and 
docosahexaenoylethanolamine (DHA-EA) have low affinity for cannabinoid receptors 38 but 
could potentially affect pain and psychological distress via other mechanisms. 2-DHG is 
abundant in nervous system tissues 42, but its specific biological actions have not yet been 
identified. DHA-EA has anti-inflammatory 25, and neurogenic 9, 20, 32 properties, and has 
been linked to improved functional recovery and reduced sensitivity to noxious heat after 
experimental spinal cord injury 15. It is not yet known whether 2-DHG or DHA-EA plays a 
role in modulating physical or psychological dimensions of the pain experience.
In the present study, we used data and samples from this completed trial to test whether 
plasma levels of 2-AG, AEA, 2-DHG and DHA-EA can be modified by diet, and whether 
such changes could help explain the beneficial effects of the H3-L6 intervention. The 
specific objectives are to: (1) determine whether the dietary interventions altered these n-3 
and n-6 derived endocannabinoids in plasma; (2) assess the relations between these 
endocannabinoids and their precursor fatty acids; and (3) examine how changes in these 
endocannabinoids related to improvements in physical, psychological, and functional 
aspects of the pain experience.
Methods
Trial overview
The trial protocol, dietary compositions, and the primary clinical and biochemical findings 
were previously described 24, 30, 31. Briefly, adults meeting the Chronic Daily Headache 
(CDH) criteria of headaches >4 hours per day and >15 days per month for at least 3 months 
and a headache history of >2 years were recruited to participate. Eligibility criteria are 
shown in Supplementary Table S1. After the nature and possible consequences of the trial 
were explained, all participants provided written informed consent. During the 4-week pre-
intervention phase, participants continued usual care and habitual diets and recorded 
headache characteristics in a web-based daily headache diary. Upon completion of the run-in 
phase, participants were randomized to either the H3-L6 intervention or L6 intervention, 
which lasted 12 weeks. Participants were masked to the nature and content of the other 
group's intervention. The dietitian was unmasked by necessity at randomization in order to 
assign patients to their group and to administer the interventions. All other investigators, 
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study personnel, and each participant's personal physician were masked to group assignment 
for the full duration of the trial. The trial was conducted at the University of North Carolina 
at Chapel Hill (UNC) from April 2009 to November 2011. Trial procedures were approved 
by the UNC Institutional Review Board. This trial is registered under ClinicalTrials.gov 
(NCT01157208).
Dietary interventions
The nutrient intakes of the H3-L6 and L6 interventions have previously been reported 24 and 
are summarized in Supplementary Table S2. The H3-L6 diet reduced dietary n-6 linoleic 
acid (LA), and concurrently increased n-3 eicosapentaenoic acid (EPA) and DHA. The L6 
diet reduced n-6 LA, and maintained low n-3 EPA and DHA intakes typical of U.S. diets 24. 
EPA and DHA were increased in the H3-L6 diet by providing fatty fish (e.g. canned fatty 
tuna). To maximize credibility, the L6 diet provided foods that were low in n-3 fatty acids 
but similar in appearance to H3-L6 foods (e.g. very low fat tuna with added oil). LA was 
reduced in both diets by restricting consumption of vegetable oils and other rich sources of 
LA. The interventions were designed to produce weight maintenance, and to be equally 
credible and equivalent with respect to macronutrient and caloric intake, interactions with 
the dietitian and investigators, and intensity and breadth of the dietary advice and web-based 
intervention materials 24. Expectation of benefit was moderate in both diet groups, with no 
between-group differences in the Borkovec and Nau credibility questionnaire 30. There were 
no significant weight changes in either group.
Sample collection and laboratory analysis of endocannabinoids and precursor fatty acids
Sample preparation and analyses were performed by investigators who were blinded to 
study protocol and clinical data. Fasting blood was drawn at baseline and after 12-weeks of 
diet exposure. Plasma aliquots were immediately frozen at -80°C. Endocannabinoids were 
analyzed via LC-MS/MS at Northeastern University's Center for Drug Discovery (Boston, 
MA) 40-42. Plasma fatty acids and the n-6 in HUFA score were previously reported [10] and 
are summarized in Supplementary Table 3.
Pain, quality of life, and psychological measures
Measures of headache pain, headache-specific quality of life (HIT-6) [16], psychological 
distress (BSI-18) 22, and health-related quality of life (SF-12) 23, 39 were collected before 
and after the intervention, and a daily headache diary was used to record hourly headache 
characteristics (rated as mild, moderate, or severe) throughout the trial, as previously 
described 19, 30 and summarized in Table 1. For each of these outcomes, the H3-L6 
intervention group experienced statistically significant improvements compared to the L6 
group 30.
Data Analysis
All analyses were conducted using Stata version 13 (College Station, Texas). We examined 
descriptive statistics for all variables, and employed a combination of non-parametric and 
parametric approaches (normalizing variables when necessary) using all available data 
without imputations. To determine whether the dietary interventions altered plasma 
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endocannabinoids, we used a Wilcoxon matched-pairs signed-ranks test to assess differences 
in pre-to-post intervention values within each diet group. To determine whether group 
assignment had an effect on the post-intervention value of each analyte, we used an analysis 
of covariance including the baseline value of each respective analyte. To determine 
associations between post-intervention plasma fatty acids and endocannabinoids, we used 
linear regressions adjusted for the baseline values of the respective fatty acid and 
endocannabinoid. To examine whether changes in endocannabinoids were related to clinical 
improvements, we used regression models adjusted for the baseline values of each outcome 
and endocannabinoid.
Results
Demographic and baseline characteristics
Sixty seven participants were randomized to the H3-L6 or the L6 diet. The groups had 
comparable baseline characteristics (Supplementary Table S5). Fifty-five participants 
completed the 12-week intervention phase and provided baseline and 12-week plasma 
measures. Endocannabinoids were measured for this sample. We compared baseline 
characteristics for these 55 completers vs. the 12 non-completers using the Wilcoxon rank-
sum test. No statistically significant differences were detected for demographic or pain-
related characteristics, however, non-completers had lower mental health scores (SF-12 
Mental Health composite score; p=0.03). At baseline, participants had high levels of 
physical pain (mean headache days per month=23 (SD=7.5), mean headache hours per 
day=10 (SD=6.4), mean severe headache hours per day=4.3 (SD=4.8), and reported taking 
an average of 6 different headache-related medications.
Abundance of endocannabinoids and their precursor fatty acids in plasma
Mean plasma endocannabinoid concentrations at baseline were as follows: 2-DHG 166 
ng/mL (SD=74.7); DHA-EA 0.47 ng/mL (SD=0.22); 2-AG 793.0 ng/mL (SD=324.1); AEA 
0.49 ng/mL (SD=0.18), with no significant between-group differences in any 
endocannabinoid (p>0.05). 2-DHG, 2-AG, DHA-EA and AEA were 0.57, 0.55, 0.0017 and 
0.00038% as abundant as their precursors DHA and AA in plasma phospholipids.
Diet-induced changes in endocannabinoids
Compared to baseline and to the L6 intervention, the H3-L6 intervention significantly 
increased 2-DHG and DHA-EA, and significantly reduced 2-AG (Table 2). The H3-L6 
intervention had no effect on AEA, oleoylethanolamine (OEA), palmitoylethanolamine 
(PEA), or oleoylglycerol (OG). The L6 intervention did not significantly alter 2-DHG, 
DHA-EA, 2-AG, AEA, OEA, PEA or OG.
Associations between plasma endocannabinoids and their precursor fatty acids
Figure 2 shows the relationships between the endocannabinoids 2-DHG, DHA-EA, 2-AG 
and AEA, and their precursor fatty acids in plasma after 12 weeks on the CDH trial. 
Increases in plasma DHA were significantly related to increases in 2-DHG and DHA-EA 
and decreases in 2-AG (p-values <0.05). Increases in plasma AA and %n6 in HUFA score 
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were significantly related to decreases in 2-DHG and DHA-EA and increases in 2-AG and 
AEA (p-values <0.05).
Association between 12-week changes in plasma endocannabinoids and clinical measures
The relationships between changes in plasma endocannabinoids and clinical measures are 
shown in Table 3. Since there was no significant effect modification by diet group, these 
associations are reported for the combined groups (Stratified results shown in 
Supplementary Table 4). For each SD increase in plasma 2-DHG, we observed a 10% 
reduction in the number of headache days per month (p=0.006) and a 40% reduction in the 
number of severe headache hours per day (p<0.001)(Table 3.a.). Increases in 2-DHG were 
also related to improvements in psychological distress (p=0.002) and the SF-12 Mental 
Health composite score (p=0.006), and tended to correlate with lower headache impact 
(p=0.051) and higher physical health (0.080)(Table 3.b.). For each SD increase in plasma 
DHA-EA, we observed a 7% reduction in the number of headache days per month (p=0.027) 
and a 30% reduction in the number of severe headache hours per day (p<0.001). However, 
unlike 2-DHG, changes in DHA-EA were not significantly related to psychological distress. 
Decreases in 2-AG were related to decreased headache severity (p=0.011), but were not 
related to any other clinical outcomes. Changes in n-3 and n-6 derived endocannabinoids 
were not significantly related to functional dimensions of pain.
Discussion
Here we report for the first time in humans that targeted alterations in dietary n-3 and n-6 
fatty acids significantly increased circulating 2-DHG and DHA-EA, and decreased 2-AG. In 
light of research demonstrating that endocannabinoids regulate many critical biochemical 
and behavioral processes in animals, the present demonstration in humans that these lipid 
mediators are modifiable by diet could have important implications for a wide range of 
pathological conditions.
Since DHA and AA are intermediates in the proposed causal pathway linking dietary fatty 
acids to their endocannabinoid products, the finding that changes in plasma 2-DHG, DHA-
EA and 2-AG were correlated with changes in their respective precursor fatty acids was not 
unexpected. In the present trial, changes in DHA seemed to be the best predictor of changes 
in both the n-3 and n-6 endocannabinoid families. The finding that changes in plasma DHA 
were positively related to DHA-derived endocannabinoids and inversely related to 2-AG is 
consistent with the model shown in Figure 1, in which DHA and AA compete for the same 
endocannabinoid biosynthetic enzymes. In this model, increased bioavailability of DHA 
produced by the H3-L6 intervention displaces AA as a substrate for endocannabinoid 
biosynthesis.
Diet-induced increases in 2-docosahexaenoylglycerol (2-DHG)
To our knowledge, the finding that plasma 2-DHG can be modified by diet is the first such 
demonstration in humans. Previous animal studies examining diet-induced alterations in 2-
DHG were inconclusive. Berger et al.7 showed that addition of DHA to DHA-free piglet 
formula increased total brain lipid 2-DHG levels by 53%, however the relevance of these pig 
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findings for human adults consuming omnivorous diets (containing some preformed DHA) 
is unclear. By contrast, Wood et al.42 found that DHA supplementation for 2 weeks in mice 
did not significantly alter plasma or brain 2-DHG, despite significant increases in DHA and 
DHA-EA. This discrepancy may be due to the longer duration of feeding (12 weeks vs. 2 
weeks) or to the concurrent lowering of dietary n-6 LA in the present trial. LA lowering may 
promote increased 2-DHG synthesis by increasing hepatic synthesis-secretion and tissue 
incorporation of the 2-DHG precursor DHA (Figure 1).
Although 2-DHG is a structural analog of the endocannabinoid 2-AG, it has low affinity for 
cannabinoid receptors 38 and specific function(s) of 2-DHG have not yet been elucidated. 
However, the relatively high concentration of 2-DHG in brain tissue 7, 42, indicates that 2-
DHG could have important functions in the brain. In the present trial, increases in 2-DHG 
correlated with reductions in headache frequency and severity, as well as psychological 
distress. Notably, these diet-induced improvements in psychological distress were selective 
for 2-DHG and were not associated with changes in 2-AG or DHA-EA. These findings are 
consistent with the hypothesis that 2-DHG might play a role in modulating physical pain and 
psychological distress. Future research into specific mechanisms of action of 2-DHG is 
needed to test this hypothesis.
Diet-induced increases in docosahexaenoylethanolamine (DHA-EA)
The demonstration in humans that DHA-EA can be modified by diet in the present trial is 
consistent with previous reports in animal models. Berger et al.7 reported that piglets fed 
formula containing n-3 DHA had higher DHA-EA levels in brain lipid extracts than piglets 
consuming DHA-free formula. Wood et al.42 showed in mice that DHA supplementation 
produced significant increases in plasma and brain DHA-EA. Figueroa et al.15 showed in 
rats that DHA supplementation increased 2-docosahexaenoyl-glycerophospoethanolamine, 
the precursor to DHA-EA, in experimental spinal cord injury (SCI). This increase was 
associated with improved functional recovery and reduced sensitivity to noxious heat. This 
link between DHA-EA and reduced pain sensitivity in experimental SCI is consistent with 
the association between increases in DHA-EA and reductions in headache frequency in the 
present trial. Importantly, however, specific mechanisms linking DHA-EA to anti-
nociception have not been identified.
In addition to these putative anti-nociceptive actions, DHA-EA has well-known anti-
inflammatory 25 and neurogenic properties. Kim et al. demonstrated that DHA-EA is a 
potent stimulator of neuritogenesis, synaptogenesis, and synaptic protein expression in 
developing hippocampal neurons 32, 34, 39. These neurogenic properties could help explain 
the finding of improved functional recovery with DHA supplementation after experimental 
SCI reported by Figueroa et al 37. In addition, these properties highlight the potential of the 
H3-L6 intervention as a therapeutic strategy that should be tested for enhancing recovery 
after traumatic brain or spinal cord injury.
Diet-induced reduction in 2-arachidonoylglycerol (2-AG)
The finding that plasma 2-AG was reduced by the H3-L6 intervention is consistent with a 
previous report that supplementation with krill oil (a source of n-3 EPA and DHA) reduced 
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plasma 2-AG in obese humans.5 However, the same group of investigators recently found 
that supplementation with krill oil powder reduced plasma AEA, but it had no effect on 2-
AG.6 Our finding of reduced 2-AG with the H3-L6 intervention is consistent with findings 
in mouse plasma 42 and brain 2 with supplemental DHA. Hibbeln et al. demonstrated 
significant reductions in liver and brain n-6 AA and 2-AG with dietary n-6 LA lowering 
alone in mice. 2 By contrast, we found in humans that n-6 lowering alone (the L6 
intervention) for 12 weeks had no effect on plasma AA or 2-AG. This discrepancy may be 
due to differences between mouse diets and omnivorous human diets which contain 
preformed AA and DHA. AA and DHA inhibit hepatic conversion of LA to AA,14 the 
precursor for 2-AG biosynthesis. Hence, dietary n-6 LA intake may be less relevant for 2-
AG biosynthesis in humans. Alternatively, 12 weeks of dietary LA-lowering may not be 
long enough to reduce circulating AA and 2-AG due to the high LA content of adipose 
tissue in the U.S. 16, 2118
The relationship between 2-AG and physical pain and psychological distress is complex and 
incompletely understood. Acute stimulation of CB-1 and CB-2 cannabinoid receptors by 2-
AG elicits anti-nociceptive22, 33 and anxiolytic 1 effects. However, 2-AG also serves as a 
major source for production free AA and pronociceptive eicosanoids 4, 28, which have been 
implicated in the pathogenesis of multiple chronic pain syndromes including headaches 3. 
Moreover, 2-AG also serves as a substrate for cyclooxygenase 2 mediated conversion into 
pro-nociceptive mediators with actions that largely opposite to known anti-nociceptive and 
anti-inflammatory actions of 2-AG 17. These observations, which highlight the complex and 
interactive nature of lipid signaling pathways, indicate that higher levels of 2-AG might 
promote nociceptive signaling in certain circumstances. Consistent with this, in a recent 
study in patients with end-stage osteoarthritis undergoing total knee arthroplasty, central 
(cerebrospinal fluid) and peripheral (synovial fluid) levels of 2-AG were significantly 
elevated in patients with higher postoperative pain, and synovial fluid 2-AG levels positively 
correlated with postoperative opioid use 4. In the present study, the findings that the 
reduction in pain in the H3-L6 group was accompanied by a reduction in plasma 2-AG, and 
that the decrease in 2-AG was associated with fewer severe headache hours, are consistent 
with the idea that 2-AG could contribute to nociceptive signaling. However, these 
relationships are complex and require further investigation.
Could the H3-L6 intervention reduce addictive risk in chronic pain patients?
Patients with chronic pain have high rates of alcohol 13 and tobacco misuse 26. Abuse of 
prescription opioids and other analgesic medications is a major public health challenge 36. In 
the present trial, the H3-L6 group experienced a major reduction in headache pain while 
reducing their use of acute pain medications 30. This group also had a reduction in plasma 
concentrations of 2-AG. Given the links between n-6 endocannabinoid hyperactivity, 
impaired satiety, craving and addiction 11, 27, the prospect of reducing 2-AG in the context 
of pain reduction as a strategy for reducing addictive tendency is appealing. These 
preliminary data suggest that the H3-L6 intervention could be investigated in future trials as 
a complementary approach for managing pain and reducing relapse in patients with chronic 
pain and comorbid opioid misuse.
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The present trial was relatively small and requires replication in a larger trial with nutrients 
altered as controlled variables. While the results clearly demonstrate that diet can alter 
circulating DHA and AA derived endocannabinoids, they cannot establish whether any of 
these endocannabinoids are causally related to improvements in pain-related clinical 
endpoints. Future studies are needed to: (1) establish whether comparable diet-induced 
biochemical alterations are possible in tissues more directly associated with physical and 
psychological dimensions of pain; (2) determine whether the magnitude of diet induced 
changes in endocannabinoid levels are physiologically relevant; (3) examine whether and 
how these lipid mediators modulate physical and psychological pain responses; (4) assess 
the relative contributions of the n-3 and n-6 derived endocannabinoids in relation to other 
lipid mediators posited to modulate inflammation and pain; (5) examine the effects of age 
and gender on the biochemical and clinical effects of the interventions; and (6) to examine 
the potential interplay between dietary n-3 and n-6 fatty acids and pain medications that alter 
fatty acid metabolism (e.g. non-steroidal anti-inflammmatory medications).
Conclusion
In summary, we found that targeted dietary changes can alter circulating 2-DHG, DHA-EA 
and 2-AG in accordance with changes in their biosynthetic precursor pools. Physical pain 
relief correlated with increases in the 2-DHG and DHA-EA, while improvements in 
psychological aspects of pain were correlated with increases in 2-DHG alone. These 
findings establish that DHA-derived endocannabinoid-like mediators are modifiable by diet 
in humans, and highlight 2-DHG and DHA-EA as lipid autacoids worthy of further 
investigation as mediators or biomarkers of physical pain and related conditions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The authors thank the patients who participated in the trial, and acknowledge the following individuals for their 
contributions: Chanee Lynch, Susan Gaylord, Chirayath Suchindran, Oli Palsson, David Barrow, Angela Johnston, 
Rebecca Coble, Meg Mangan, Beth Fowler, Carol Carr, Regina McCoy, Tim McCaskill, Gus Swenson, Marjorie 
Busby, Ameer Taha, Stanley Rapoport and Mark Horowitz. This project was supported by the Mayday Fund 
(primary funding source); the UNC Research Fellowship in Complementary and Alternative Medicine (grant T32-
AT003378, NCCAM, NIH); the North Carolina Clinical and Translational Sciences Institute (grant UL1RR025747, 
NCRR, NIH); the UNC Nutrition Obesity Research Center, CHAI Core (grant DK056350, NIDDK, NIH); the 
National Institute on Drug Abuse (DA07215 and DA09158); and the Intramural Program of the National Institute 
on Alcohol Abuse and Alcoholism, National Institutes of Health. The content is solely the responsibility of the 
authors and does not necessarily represent the official views of the National Institutes of Health.
Disclosures: Research Funding: This project was supported by the Mayday Fund (primary funding source); the 
UNC Research Fellowship in Complementary and Alternative Medicine (grant T32-AT003378, NCCAM, NIH); 
the North Carolina Clinical and Translational Sciences Institute (grant UL1RR025747, NCRR, NIH); the UNC 
Nutrition Obesity Research Center, CHAI Core (grant DK056350, NIDDK, NIH); the National Institute on Drug 
Abuse (DA07215 and DA09158); and the Intramural Program of National Institute on Alcohol Abuse and 
Alcoholism, National Institutes of Health.
Ramsden et al. Page 9














1. Almeida-Santos AF, Gobira PH, Rosa LC, Guimaraes FS, Moreira FA, Aguiar DC. Modulation of 
anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral 
periaqueductal gray. Behavioural brain research. 2013; 252:10–17. [PubMed: 23714073] 
2. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, Madsen L, Kristiansen K, 
Froyland L, Hibbeln JR. Dietary linoleic acid elevates endogenous 2-AG and anandamide and 
induces obesity. Obesity. 2012; 20:1984–1994. [PubMed: 22334255] 
3. Antonova M, Wienecke T, Olesen J, Ashina M. Prostaglandin E(2) induces immediate migraine-like 
attack in migraine patients without aura. Cephalalgia: an international journal of headache. 2012; 
32:822–833. [PubMed: 22718556] 
4. Azim S, Nicholson J, Rebecchi MJ, Galbavy W, Feng T, Reinsel R, Volkow ND, Benveniste H, 
Kaczocha M. Endocannabinoids and acute pain after total knee arthroplasty. Pain. 2015; 156:341–
347. [PubMed: 25599456] 
5. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, Sirigu AR, Berge K, Vik H, Maki KC, Di 
Marzo V, Griinari M. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese 
subjects. Nutrition & metabolism. 2011; 8:7. [PubMed: 21276269] 
6. Berge K, Piscitelli F, Hoem N, Silvestri C, Meyer I, Banni S, Di Marzo V. Chronic treatment with 
krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids in 
health and disease. 2013; 12:78. [PubMed: 23706001] 
7. Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: inclusion 
of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding 
N-acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United 
States of America. 2001; 98:6402–6406. [PubMed: 11353819] 
8. Burston JJ, Woodhams SG. Endocannabinoid system and pain: an introduction. The Proceedings of 
the Nutrition Society. 2014; 73:106–117. [PubMed: 24148358] 
9. Cao D, Kevala K, Kim J, Moon HS, Jun SB, Lovinger D, Kim HY. Docosahexaenoic acid promotes 
hippocampal neuronal development and synaptic function. Journal of neurochemistry. 2009; 
111:510–521. [PubMed: 19682204] 
10. De Petrocellis L, Schiano Moriello A, Imperatore R, Cristino L, Starowicz K, Di Marzo V. A re-
evaluation of 9-HODE activity at TRPV1 channels in comparison with anandamide: 
enantioselectivity and effects at other TRP channels and in sensory neurons. British journal of 
pharmacology. 2012; 167:1643–1651. [PubMed: 22861649] 
11. De Vries TJ, Schoffelmeer AN. Cannabinoid CB1 receptors control conditioned drug seeking. 
Trends in pharmacological sciences. 2005; 26:420–426. [PubMed: 15992935] 
12. Derogatis, L. BSI-18: Administration, Scoring, and Procedures Manual. Minneapolis, MN: 
National Computer Systems; 2000. 
13. Egli M, Koob GF, Edwards S. Alcohol dependence as a chronic pain disorder. Neuroscience and 
biobehavioral reviews. 2012; 36:2179–2192. [PubMed: 22975446] 
14. Emken EA, Adlof RO, Duval SM, Nelson GJ. Effect of dietary docosahexaenoic acid on 
desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male 
subjects. Lipids. 1999; 34:785–791. [PubMed: 10529088] 
15. Figueroa JD, Cordero K, Serrano-Illan M, Almeyda A, Baldeosingh K, Almaguel FG, De Leon M. 
Metabolomics uncovers dietary omega-3 fatty acid-derived metabolites implicated in anti-
nociceptive responses after experimental spinal cord injury. Neuroscience. 2013; 255:1–18. 
[PubMed: 24042033] 
16. Garland M, Sacks FM, Colditz GA, Rimm EB, Sampson LA, Willett WC, Hunter DJ. The relation 
between dietary intake and adipose tissue composition of selected fatty acids in US women. The 
American journal of clinical nutrition. 1998; 67:25–30. [PubMed: 9440371] 
17. Guindon J, Hohmann AG. A physiological role for endocannabinoid-derived products of 
cyclooxygenase-2-mediated oxidative metabolism. British journal of pharmacology. 2008; 
153:1341–1343. [PubMed: 18297102] 
Ramsden et al. Page 10













18. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans 
and its use as a biomarker of dietary intake. Progress in lipid research. 2008; 47:348–380. 
[PubMed: 18435934] 
19. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K. Psychometric properties of 
the HIT-6 among patients in a headache-specialty practice. Headache. 2005; 45:638–643. 
[PubMed: 15953295] 
20. Kim HY, Moon HS, Cao D, Lee J, Kevala K, Jun SB, Lovinger DM, Akbar M, Huang BX. N-
Docosahexaenoylethanolamide promotes development of hippocampal neurons. The Biochemical 
journal. 2011; 435:327–336. [PubMed: 21281269] 
21. Kingsbury K, Paul S, Morgan DM, Crossley A. Fatty Acid Composition of Human Depot Fat. 
Biochemical Journal. 1961; 78:541–&. [PubMed: 13756126] 
22. LR, D. BSI-18: Administration, Scoring, and Procedures Manual. Minneapolis, MN: National 
Computer Systems; 2000. 
23. Luo X, George ML, Kakouras I, Edwards CL, Pietrobon R, Richardson W, Hey L. Reliability, 
validity, and responsiveness of the short form 12-item survey (SF-12) in patients with back pain. 
Spine. 2003; 28:1739–1745. [PubMed: 12897502] 
24. MacIntosh BA, Ramsden CE, Faurot KR, Zamora D, Mangan M, Hibbeln JR, Mann JD. Low-n-6 
and low-n-6 plus high-n-3 diets for use in clinical research. The British journal of nutrition. 2013; 
110:559–568. [PubMed: 23328113] 
25. Meijerink J, Plastina P, Vincken JP, Poland M, Attya M, Balvers M, Gruppen H, Gabriele B, 
Witkamp RF. The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows 
immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new 
link between fish oil and inflammation. The British journal of nutrition. 2011; 105:1798–1807. 
[PubMed: 21294934] 
26. Mitchell MD, Mannino DM, Steinke DT, Kryscio RJ, Bush HM, Crofford LJ. Association of 
smoking and chronic pain syndromes in Kentucky women. The journal of pain: official journal of 
the American Pain Society. 2011; 12:892–899. [PubMed: 21816352] 
27. Mitrirattanakul S, Lopez-Valdes HE, Liang J, Matsuka Y, Mackie K, Faull KF, Spigelman I. 
Bidirectional alterations of hippocampal cannabinoid 1 receptors and their endogenous ligands in a 
rat model of alcohol withdrawal and dependence. Alcoholism, clinical and experimental research. 
2007; 31:855–867.
28. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, Ward AM, 
Hahn YK, Lichtman AH, Conti B, Cravatt BF. Endocannabinoid Hydrolysis Generates Brain 
Prostaglandins That Promote Neuroinflammation. Science. 2011; 334:809–813. [PubMed: 
22021672] 
29. Ramsden CE, Faurot KR, Zamora D, Palsson OS, MacIntosh BA, Gaylord S, Taha AY, Rapoport 
SI, Hibbeln JR, Davis JM, Mann JD. Targeted alterations in dietary n-3 and n-6 fatty acids 
improve life functioning and reduce psychological distress among patients with chronic headache: 
a secondary analysis of a randomized trial. Pain. 2015; 156:587–596. [PubMed: 25790451] 
30. Ramsden CE, Faurot KR, Zamora D, Suchindran CM, Macintosh BA, Gaylord S, Ringel A, 
Hibbeln JR, Feldstein AE, Mori TA, Barden A, Lynch C, Coble R, Mas E, Palsson O, Barrow DA, 
Mann JD. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic 
headaches: a randomized trial. Pain. 2013; 154:2441–2451. [PubMed: 23886520] 
31. Ramsden CE, Mann JD, Faurot KR, Lynch C, Imam ST, MacIntosh BA, Hibbeln JR, Loewke J, 
Smith S, Coble R, Suchindran C, Gaylord SA. Low omega-6 vs. low omega-6 plus high omega-3 
dietary intervention for chronic daily headache: protocol for a randomized clinical trial. Trials. 
2011; 12:97. [PubMed: 21496264] 
32. Rashid MA, Katakura M, Kharebava G, Kevala K, Kim HY. N-Docosahexaenoylethanolamine is a 
potent neurogenic factor for neural stem cell differentiation. Journal of neurochemistry. 2013; 
125:869–884. [PubMed: 23570577] 
33. Rea K, Olango WM, Okine BN, Madasu MK, McGuire IC, Coyle K, Harhen B, Roche M, Finn 
DP. Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-
dependent hyper-responsivity to noxious stimuli. Pain. 2014; 155:69–79. [PubMed: 24076311] 
Ramsden et al. Page 11













34. Salem N Jr, Pawlosky R, Wegher B, Hibbeln J. In vivo conversion of linoleic acid to arachidonic 
acid in human adults. Prostaglandins, leukotrienes, and essential fatty acids. 1999; 60:407–410.
35. Sastry PS. Lipids of nervous tissue: composition and metabolism. Progress in lipid research. 1985; 
24:69–176. [PubMed: 3916238] 
36. Schultz D. Opioid use and abuse: a pain clinic perspective. Minnesota medicine. 2013; 96:42–44. 
[PubMed: 23930469] 
37. Stark KD. The percentage of n-3 highly unsaturated fatty acids in total HUFA as a biomarker for 
omega-3 fatty acid status in tissues. Lipids. 2008; 43:45–53. [PubMed: 17985169] 
38. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, 
Baba N, Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol 
receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and 
related compounds. The Journal of biological chemistry. 1999; 274:2794–2801. [PubMed: 
9915812] 
39. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales 
and preliminary tests of reliability and validity. Med Care. 1996; 34:220–233. [PubMed: 8628042] 
40. Williams J, Wood J, Pandarinathan L, Karanian DA, Bahr BA, Vouros P, Makriyannis A. 
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric 
pressure chemical ionization-MS. Analytical chemistry. 2007; 79:5582–5593. [PubMed: 
17600384] 
41. Wood JT, Williams JS, Pandarinathan L, Courville A, Keplinger MR, Janero DR, Vouros P, 
Makriyannis A, Lammi-Keefe CJ. Comprehensive profiling of the human circulating 
endocannabinoid metabolome: clinical sampling and sample storage parameters. Clinical 
chemistry and laboratory medicine: CCLM/FESCC. 2008; 46:1289–1295. [PubMed: 18611105] 
42. Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, Makriyannis A. Dietary 
docosahexaenoic acid supplementation alters select physiological endocannabinoid-system 
metabolites in brain and plasma. Journal of lipid research. 2010; 51:1416–1423. [PubMed: 
20071693] 
Ramsden et al. Page 12














• Endocannabinoids have analgesic, anxiolytic, and neurogenic properties.
• Endocannabinoids derived from n-3 and n-6 fatty acids can be modified by diet 
in humans.
• Diet induced changes in n-3 derived endocannabinoids correlated with clinical 
improvement.
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Figure 1. Model depicting diet-induced alterations in n-3 and n-6 derived endocannabinoids
(A) Dietary n-3 and n-6 polyunsaturated fatty acids compete for enzymatic conversion into 
their respective elongated and desaturated products, notably n-3 DHA and n-6 AA.
(B) n-3 DHA and EPA and n-6 AA and LA compete for esterification into cell membranes.
(C) Membrane n-3 DHA and n-6 AA are converted to their respective glycerol-ester and N-
acylethanolamine endocannabinoids in proportion to available substrate.
(D) n-3 and n-6 fatty acids can be converted to numerous other lipid autacoids with pro- or 
anti-nociceptive properties (eg, prostaglandins, EETs, HODEs, lipoxins, resolvins, 
protectins).
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; AA, 
arachidonic acid; DHG, docosahexaenoylglycerol; DHA-EA, 
docosahexaenoylethanolamine; AG, arachidonoylglycerol; AEA, 
arachidonoylethanolamine; EET, epoxyeicosatrienoic acid; HODE, hydroxyoctadecadienoic 
acid; CB, cannabinoid; TRPV1, transient receptor potential cation channel, subfamily V, 
member 1.
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Figure 2. Precursor fatty acids and their n-3 and n-6 endocannabinoid products in plasma after 
12 weeks
Plots are post-estimations of linear regression models for the effect plasma fatty acids on 
each endocannabinoid after 12 weeks on the Chronic Daily Headache Study (n=55), 
adjusting for the baseline value of each respective endocannabinoid and fatty acid. 
Endocannabinoids are measured in ng/mL.
The shaded areas around regression lines are 95% confidence intervals. DHG, 
docosahexaenoylglycerol; DHA-EA, docosahexaenoylethanolamine; 2-AG, 2-
arachidonoylglycerol; AEA, arachidonoylethanolamine; DHA, docosahexaenoic acid; n-6, 
omega-6; HUFA, highly unsaturated fatty acids.
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Table 1
Description of clinical outcomes in the chronic daily headache trial
Description Time points Baseline mean (SD)
Pain frequency and intensity





 Headache hours/day Calculated from web-based daily Headache 
Diary recording hourly headache characteristics 
(rated as mild, moderate, or severe). Mean 
Headache Hours per day and Severe Headache 
Hours per day were calculated by averaging the 
last 4 weeks before randomization and during 
intervention weeks eight through 12.
Recorded daily 
throughout the run-in 
and intervention 
phases (112 days 
total)
10.2 (6.4)
Severe headache hours/day 4.3 (4.8)
Functional dimensions of pain
 Headache Impact on quality of life 
(HIT-6)
Measure of headache-related disability based on 
self-reported pain, social functioning, role 





 Physical Health Composite Score 
(SF-12)
Summary measure for quality of life, function 




Psychological dimensions of pain
 Mental Health Composite Score 
(SF-12)
Summary measure for quality of life, function 





 Psychological distress (BSI-18) Measure of general psychological distress over 
the last 7 days by each of 18 symptoms, 
including separate scores for anxiety, depression, 
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Table 3
a. Associations between 12-week changes in endocannabinoids and physical pain (n=55)
n-3 DHA-derived1 (ng/mL) n-6 AA derived1 (ng/mL)
2-DHG DHA-EA 2-AG AEA
Headache days/month (n=55) -10% (0.006) -7% (0.027) -6% (0.191) -2% (0.533)
Headache hours/day (n=51) -12% (0.031) -3% (0.642) 13% (0.068) 8% (0.175)
Severe headache hours/day (n=51) -40% (<0.001) -30% (<0.001) 39% (0.011) 34% (0.001)
1Standardized coefficients represent the % change in count (i.e., days or hours) for each standard deviation change in the respective 
endocannabinoid (p-values in parenthesis) and are derived from Poisson regression models relating endocannabinoids and headache outcomes 
at week 12 and adjusting for the respective baseline values.
b. Associations between 12-week changes in endocannabinoids and pain-related quality of life measures and psychological stress – both 
groups (n=55)
n-3 DHA-derived1 n-6 AA derived1
2-DHG DHA-EA 2-AG AEA
Functional dimensions of pain
Headache Impact on quality of life 
(HIT-6)2
-0.23 (0.051) -0.19 (0.089) 0.21 (0.124) 0.12 (0.332)
Physical Health Composite Score 
(SF-12)3
0.21 (0.080) 0.16 (0.171) -0.17 (0.231) -0.19 (0.125)
Psychological dimensions of pain
Mental Health Composite Score 
(SF-12)3
0.34 (0.006) 0.11 (0.346) -0.002 (0.986) 0.01 (0.912)
Psychological distress (BSI)4 -0.36 (0.002) -0.16 (0.138) 0.12 (0.351) 0.15 (0.205)
1
Standardized coefficients represent a standard deviation change in the outcome variable for each one standard deviation increase in the respective 
endocannabinoid (p-values in parenthesis) and are derived from linear regression models relating endocannabinoids and outcomes at week 12 and 
adjusting for the respective baseline values.
2
Higher score = more headache impact on quality of life.
3
Higher score = better quality of life.
4
Higher score = more psychological distress.
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